Product Decisions This Supports
- Feature-level: Adds month-and-year granularity to admin CRUD forms where a full date picker is wrong — billing periods, fiscal/reporting months, payroll cycles, subscription start/end months, compliance or contract effective months, cohort tagging, and expiration-month fields.
- Build vs. buy: This is a strong borrow case rather than a build case. The user-facing feature is small (a Nova field wrapping a month/year selector), so the decision is really "adopt a tiny OSS field" vs. "spend a few hours writing a custom Nova field." It rarely justifies a bespoke build unless you need behavior it does not provide.
- Roadmap prioritization: Supports deferring custom admin-tooling work. If Nova is already in the stack and ops/finance users need period selectors, this unblocks internal workflows without committing roadmap capacity to admin UI polish.
- Standardization: Encourages one canonical "month" field type across models, reducing ad-hoc string parsing, inconsistent
YYYY-MM vs. MM/YYYY storage, and downstream reporting bugs.
- Vendor/risk decision: Low stars, zero dependents, and a last release in April 2022 make this an explicit "vendor or fork" input — it is a candidate to copy into your codebase rather than track as an external dependency.
- Use cases it does not support: Anything needing day-level precision, date ranges, time zones, recurring schedules, or multi-calendar/localized month names.
When to Consider This Package
Consider it when:
- You are already running Laravel Nova — this is a Nova field and has no value outside that admin panel.
- The requirement is genuinely month + year only, stored as a single period value, and a full date picker would create bad data (users picking arbitrary days).
- The consumer is internal ops/admin staff, so a small, unmaintained UI control has limited blast radius.
- You are willing to pin the version, vendor/fork the code, or wrap it — treat it as sample code you own rather than a maintained dependency.
- You have verified Nova version compatibility; a 2022 release is likely targeting Nova 3/4 and should be tested against your installed major version.
Look elsewhere (or build ~a day of custom field work) when:
- Nova is not part of your stack, or you are on a Nova major version this field predates.
- You need maintained releases, security patching, CI, test coverage, or an active issue tracker — none of which this package demonstrates (0 stars, 0 dependents, no releases since 2022).
- You need localization, calendar systems, quarter/period logic, min/max range constraints, or validation beyond basic month selection.
- The field feeds customer-facing or financial-calculation-critical paths where an unmaintained UI dependency is unacceptable.
- You need date ranges or duration math (e.g., "last 13 weeks"), which a single month selector cannot express.
How to Pitch It (Stakeholders)
For executives: This is a very small, free admin-panel component that lets internal teams record months instead of exact dates — useful for billing periods, reporting cycles, and renewal months. Cost is effectively zero and the feature is low-risk because it only touches internal admin screens. The main caveat is that it is a hobby-scale open-source project with no recent releases, so we should plan to own a copy rather than depend on the author. Worst case, replacing it is on the order of a day of engineering.
For engineering: A Nova field wrapping a month/year selector. Tiny surface area, no meaningful dependency graph (0 dependents), last shipped April 2022 — so assume no upstream maintenance. Recommended posture: pin it, smoke-test against our Nova version, and be ready to fork or inline it. Do not let it become a transitive dependency of anything outside the admin panel, and do not build reporting or billing logic on top of its stored format without a normalization layer.
Recommendation: Adopt narrowly as an internal admin convenience, or skip adoption and copy the pattern into a first-party field. Do not treat it as a strategic or long-lived dependency; the decision is reversible at near-zero cost, which is precisely why it is safe to trial.